This leaves the door wide open for downgrades, which could pressure MNK shares even lower. Bristol-Myers Squibb stock is also near the bottom of the SPX, down 4.5% at $52.51. The company presented an update for its Opdivo-Yervoy …
09/08 Bristol-Myers Squibb Company $BMY Stock Rating Reaffirmed by Goldman Sachs Gr.. 09/07 BRIEF-Bristol
Shares of Bristol-Myers Squibb Co. (ticker: BMY) fell more than 16 percent Friday after the company announced that its Opdivo drug failed a study that would have expanded its use to lung cancer patients. BMY stock dropped more than …
Bristol-Myers Squibb (NYSE: BMY) investors might have been just a bit worried on Wednesday. After all, the U.S. Food and Drug Administration (FDA) had just placed a partial clinical hold on three clinical trials for Opdivo in combination …
NWI14d
Bristol Myers Squibb Co. (NYSE:BMY) is down 5% so far this year, as the company saw bad news break in early August when it suspended a trial for its prospective drug for treating hepatitis C following safety concerns. This followed Bristol
Bristol-Myers Squibb's stock fell nearly 10 percent yesterday after the company released a disappointing earnings forecast. The news helped send the prices of other drug stocks tumbling. . The shares of the Bristol-Myers Squibb …
Carl Icahn didn't amass a net worth of an estimated $16.6 billion by making dumb moves. So when Dow Jones reported that the billionaire bought a stake in Bristol-Myers Squibb (NYSE: BMY), it captured the attention of the investment …
U.S. stock market report [.N] 1058 ET 11Nov2008-Bristol-Myers stock drops after Avapro study results ----- Shares of Bristol-Myers Squibb Co (BMY.N) dropped 2 percent to $19.97 on ...
... you teach ethics to MBA students while helping an indicted CFO accused of inflating the price of Bristol-Myers Squibb (BMY) stock? If you're Glenn Hubbard, dean of the Columbia Graduate School of Business, the answer is yes. …